Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact